Neurology pp 274-281 | Cite as

Epidemiology of Parkinson’s Disease

  • R. J. Marttila
  • U. K. Rinne
Conference paper

Abstract

During the last three decades, there has been an increasingly productive interest in epidemiological research into Parkinson’s disease (PD); as a result, a number of descriptive and analytical epidemiological studies have been recently completed. Although the epidemiological profile of PD is not yet fully elucidated, these studies have appreciably advanced our knowledge of the epidemiological indices and natural course of PD, and furnished some clues relating to the unknown cause of the disease.

Keywords

Depression Dopamine Dementia Nicotine Neurol 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Baumann RJ, Jameson HD, McKean HE, Haack DG, Weisberg LM (1980) Cigarette smoking and Parkinson’s disease. 1. A comparison of cases with matched neighbors. Neurology 30: 839–843PubMedGoogle Scholar
  2. 2.
    Bernheimer H, Birkmayer W, Hornykiewicz O, Jellinger K, Seitelberger F (1973) Brain dopamine and syndrome of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J Neurol Sci 20: 415–455PubMedCrossRefGoogle Scholar
  3. 3.
    Brewis M, Poskanzer DC, Rolland C, Miller H (1966) Neurological disease in an English city. Acta Neurol Scand [suppl 24]: 1–89Google Scholar
  4. 4.
    Dimsdale H (1946) Changes in the parkinsonian syndrome in the twentieth century. Q J Med 15: 155–170PubMedGoogle Scholar
  5. 5.
    Dupont E (1977) Epidemiology of parkinsonism: the Parkinson investigation, Arhus, Denmark. In: Worm-Petersen J, Böttcher J (eds) Symposium on Parkinsonism. Merck, Sharp and Dohme, Denmark, pp 65–75Google Scholar
  6. 6.
    Duvoisin RC, Yahr MD (1965) Encephalitis and parkinsonism. Arch Neurol 12: 227–239PubMedGoogle Scholar
  7. 7.
    Godwin-Austen RB, Lee PN, Marmot MG, Stern GM (1982) Smoking and Parkinson’s disease. J Neurol Neurosurg Psychiatry 45: 577–581PubMedCrossRefGoogle Scholar
  8. 8.
    Gudmundsson KRA (1967) A clinical survey of Parkinsonism in Iceland. Acta Neurol Scand 43 [suppl 33]: 9–61CrossRefGoogle Scholar
  9. 9.
    Haack DG, Baumann RJ, McKean HE, Jameson HD, Turbek JA (1981) Nicotine exposure and Parkinson’s disease. Am J Epidemiol 114: 191–200PubMedGoogle Scholar
  10. 10.
    Harada H, Nishikawa S, Takahashi K (1983) Epidemiology of Parkinson’s disease in a Japanese city. Arch Neurol 40: 151–154PubMedGoogle Scholar
  11. 11.
    Hoehn MM, Yahr MD (1967) Parkinsonism: onset, progression, and mortality. Neurology 17: 427–442PubMedGoogle Scholar
  12. 12.
    Jenkins AC (1966) Epidemiology of Parkinsonism in Victoria. Med J Aust 2: 496–502PubMedGoogle Scholar
  13. 13.
    Kessler II (1972) Epidemiologic studies of Parkinson’s disease. II. Hospital based survey. Am J Epidemiol 95: 308–318PubMedGoogle Scholar
  14. 14.
    Kessler II (1972) Epidemiologic studies of Parkinson’s disease. III. A community based survey. Am J Epidemiol 96: 242–254PubMedGoogle Scholar
  15. 15.
    Kessler II, Diamond EL (1971) Epidemiologic studies of Parkinson’s disease. I. Smoking and Parkinson’s disease: a survey and explanatory hypothesis. Am J Epidemiol 94: 16–25PubMedGoogle Scholar
  16. 16.
    Kondo K (1984) Epidemiological clues for the etiology of Parkinson’s disease. Adv Neurol 40: 345–351PubMedGoogle Scholar
  17. 17.
    Kondo K, Shibasaki H (1981) Epidemiology of Parkinson’s disease. Clues for etiology. 12th World congress of neurology, International Congress Series 548. Excerpta Medica, Amsterdam, p 233Google Scholar
  18. 18.
    Kurland LT (1958) Epidemiology: incidence geographic distribution and genetic considerations. In: Fields WJ (ed) Pathogenesis and treatment of Parkinsonism. Charles C. Thomas, Springfield, 111, pp 5–49Google Scholar
  19. 19.
    Kurtzke JF, Kurland LT (1981) The epidemiology of neurologic disease. In: Baker AB, Baker LH (eds) Clinical neurology, vol 3, chap 48. Harper and Row, New YorkGoogle Scholar
  20. 20.
    Langston JW, Ballard P, Tetrud JW, Irwin I (1983) Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219: 979–980PubMedCrossRefGoogle Scholar
  21. 21.
    Li S, Schoenberg BS, Wang C, Cheng X, Rui D, Bolis CL, Schoenberg DG (1985) A prevalence survey of Parkinson’s disease and other movement disorders in the People’s Republic of China. Arch Neurol 42: 655–657PubMedGoogle Scholar
  22. 22.
    Lipkin LE (1959) Cytoplasmic inclusions in ganglion cells associated with parkinsonian states: a neurocellular change studied in 53 cases and 206 controls. Am J Pathol 35: 1117–1133PubMedGoogle Scholar
  23. 23.
    Maier Hoehn MM (1985) Result of chronic levodopa therapy and its modification by bromocriptine in Parkinson’s disease. Acat Neurol Scand 71: 97–106CrossRefGoogle Scholar
  24. 24.
    Marttila RJ, Rinne UK (1976) Epidemiology of Parkinson’s disease in Finland. Acta Neurol Scand 53: 81–102PubMedCrossRefGoogle Scholar
  25. 25.
    Marttila RJ, Rinne UK (1976) Arteriosclerosis, heredity, and some previous infections in the etiology of Parkinson’s disease. A case-control study. Clin Neurol Neurosurg 76: 46–56CrossRefGoogle Scholar
  26. 26.
    Marttila RJ, Rinne UK (1979) Changing epidemiology of Parkinson’s disease: predicted effects of levodopa treatment. Acta Neurol Scand 59: 80–87PubMedCrossRefGoogle Scholar
  27. 27.
    Marttila RJ, Rinne UK (1980) Smoking and Parkinson’s disease. Acta Neurol Scand 62: 322–325PubMedCrossRefGoogle Scholar
  28. 28.
    Marttila RJ, Rinne UK (1985) Clues from the epidemiology of Parkinson’s disease. Adv Neurol (in press)Google Scholar
  29. 29.
    Marttila RJ, Rinne UK, Siirtola T, Sonninen V (1977) Mortality of patients with Parkinson’s disease treated with levodopa. J Neurol 216: 147–153PubMedCrossRefGoogle Scholar
  30. 30.
    Mutch W(1985) Parkinson’s disease in Aberdeen; 1983–1984. In: Social, epidemiological and therapeutic aspects of Parkinson’s disease. Abstracts. 5 Feb 1985, LondonGoogle Scholar
  31. 31.
    Nobrega FT, Glattre E, Kurland LT, Okazaki H (1969) Comments on the epidemiology of parkinsonism including prevalence and incidence statistics for Rochester, Minnesota, 1935–1966. In: Barbeau A, Brünetter JR (eds) Progress in neuro-genetics. Excerpta Medica, Amsterdam, pp 474–485Google Scholar
  32. 32.
    dePedro J, Rosenqvist U (1984) Tracers for paralysis agitans in epidemiological research. II. A model for indirect estimation of the prevalence of the disease. Neuroepid 3: 97–107CrossRefGoogle Scholar
  33. 33.
    Pollock M, Hornabrook RW (1966) The prevalence, natural history and dementia of Parkinson’s disease. Brain 89: 429–448PubMedCrossRefGoogle Scholar
  34. 34.
    Poskanzer DC, Schwab RS (1963) Cohort analysis of Parkinson’s disease. Evidence for a single etiology related to subclinical infection about 1920. J Chron Dis 16: 961–973PubMedCrossRefGoogle Scholar
  35. 35.
    Pritchard PB, Netsky MG (1973) Prevalence of neoplasms and causes of death in paralysis agitans. Neurology 23: 215–222PubMedGoogle Scholar
  36. 36.
    Rajput AH, Offord KP, Beard CM, Kurland LT (1984) Epidemiology of parkinsonism: incidence, classification, and mortality. Ann Neurol 16: 278–282PubMedCrossRefGoogle Scholar
  37. 37.
    Reef HE (1977) Prevalence of Parkinson’s disease in a multiracial community. In: den Hartog Jager WA, Bruyn GW, Heijstee APJ (eds) 11th World congress of neurology. Excerpta Medica, Amsterdam, p 125Google Scholar
  38. 38.
    Rosati G, Granieri E, Pinna L, Aiello L, Tola R, De Bastini P, Pirisi A, Devoto MC (1980) The risk of Parkinson disease in Mediterranean people. Neurology 30: 250–255PubMedGoogle Scholar
  39. 39.
    Schoenberg BS, Anderson DW, Haerer AF (1982) Differences by race in the prevalence of Parkinson’s disease. Abstracts of the 7th international symposium on Parkinson’s disease, 27–30 June 1982, Frankfurt a. M., p 55Google Scholar
  40. 40.
    Schoenberg BS, Anderson DW, Haerer AF (1985) Prevalence of Parkinson’s disease in the biracial population of Copiah County, Mississippi. Neurology 35: 841–845PubMedGoogle Scholar
  41. 41.
    Sweet RD, McDowell RH (1975) Five years’ treatment of Parkinson’s disease with levo- dopa. Ann Intern Med 83: 456–463PubMedGoogle Scholar
  42. 42.
    Todes CJ, Lees AJ (1985) The pre-morbid personality of patients with Parkinson’s disease. J Neurol Neurosurg Psychiatry 48: 97–100PubMedCrossRefGoogle Scholar
  43. 43.
    Ward CD, Duvoisin RC, Ince SE, Nutt JD, Eldridge R, Calne DB (1983) Parkinson’s disease in 65 pairs of twins and in a set of quadruplets. Neurology 33: 815–824PubMedGoogle Scholar
  44. 44.
    Ward CD, Duvoisin RC, Ince SE, Nutt JD, Eldridge R, Calne DB, Dambrosia J (1984) Parkinson’s disease in twins. Adv Neurol 40: 341–344PubMedGoogle Scholar
  45. 45.
    Yahr MD (1976) Evaluation of long-term therapy in Parkinson’s disease. Mortality and therapeutic efficacy. In: Birkmayer W, Hornykiewicz O (eds) Advances in Parkinsonism. Editiones Roche, Basle, pp 435–443Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1986

Authors and Affiliations

  • R. J. Marttila
  • U. K. Rinne
    • 1
  1. 1.Department of NeurologyUniversity of TurkuTurkuFinland

Personalised recommendations